Prevenar 13® | Shim Clinic, Singapore

Prevenar 13® | Shim Clinic, Singapore: PCV13 / Pneumococcal 13-valent (Diphtheria CRM197 Protein) Conjugate vaccine jab/shot/injection schedule, to vaccinate against the Streptococcus pneumoniae types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F, to immunise against pneumonia and pneumococcal infection clinic, Singapore. Private and confidential service. Definitions, references, and latest news.

Vaccine	Against	Disease	Age	D o s e s	Dose schedule	Price per dose (SG$)
Live attenuated
MMR vaccine			≥12m	1		$70/=
Measles vaccine	Measles virus	Measles
Mumps vaccine	Mumps virus	Mumps
Rubella vaccine	Rubella virus	Rubella
Varilrix™ Varicella vaccine Chickenpox vaccine	Varicella zoster virus HHV-3	Varicella Chickenpox	12m-12y	1		$121/=
Varilrix™ Varicella vaccine Chickenpox vaccine		Varicella Chickenpox	≥13y	2	6-10w interval	$121/=
Zostavax™ Herpes zoster vaccine Shingles vaccine		Herpes zoster Shingles	≥50y	1		$400/=
Stamaril® Yellow fever vaccine	Yellow fever virus	Yellow fever	9m-59y	1	10 yearly	$250/=
Inactivated / Whole / Viral & Bacterial
Ixiaro® Japanese encephalitis vaccine JE vaccine	Japanese encephalitis virus	Japanese encephalitis	≥17y	2	2nd: 28d after 1st	$386/=
Ixiaro® Japanese encephalitis vaccine JE vaccine	Japanese encephalitis virus	Japanese encephalitis	≥17y	1	Booster: 12-24m after 2nd	$386/=
Dukoral® Cholera vaccine	Vibrio cholerae	Cholera	2-6y	3	1-6w interval	$113/=
			2-6y	1	Booster: 6m after 3rd
			≥6y	2	1-6w interval
			≥6y	1	Booster: 2y after 2nd
Inactivated / Fractional / Protein
Intanza™ Influenza vaccine	Influenza virus	Influenza	18-59y	1	1 yearly	$30/=
Fluarix™ Influenza vaccine	Influenza virus	Influenza	6-36m	½	1 yearly	$30/=
Fluarix™ Influenza vaccine	Influenza virus	Influenza	>3y	1	1 yearly	$30/=
Tetavax Tetanus vaccine	Clostridium tetani	Tetanus	adults	3	1-2m interval 3rd @ 6-12m after 2nd	$30/=
Tetavax Tetanus vaccine	Clostridium tetani	Tetanus	booster	1	10 yearly	$30/=
Boostrix® Tdap vaccine DPT vaccine DTP vaccine			≥4y	1	<10 yearly	$70/=
Diphtheria vaccine	Corynebacterium diphtheriae	Diphtheria
Tetanus vaccine	Clostridium tetani	Tetanus
Pertussis vaccine Whooping cough vaccine	Bordetella pertussis	Pertussis Whooping cough
Inactivated / Fractional / Polysaccharide / Pure
Typhim Vi® Typhoid vaccine	Salmonella typhi	Typhoid fever	>5y	1	3 yearly	$40/=
Mencevax® ACWY MPSV4 Meningococcal Polysaccharide vaccine MPSV Meningococcal Meningitis vaccine Meningococcal vaccine Meningitis vaccine	Neisseria meningitidis types A, C, W-135 and Y	Meningococcal meningitis	>2y	1		$80/=
Inactivated / Fractional / Polysaccharide / Conjugate
Menactra® MCV4 Meningococcal conjugate vaccine MCV Meningococcal Meningitis vaccine Meningococcal vaccine Meningitis vaccine	Neisseria meningitidis types A, C, W-135 and Y	Meningococcal meningitis	2-55y	1		$220/=
Prevenar 13® (SG) / Prevnar 13® (US) PCV13 Pneumococcal conjugate vaccine PCV Pneumococcal Pneumonia vaccine Pneumococcal vaccine Pneumonia vaccine	Streptococcus pneumoniae types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F	Pneumococcal infection	6w-6m	4	1m interval 4th @ 12-15m	$274/=
			7-11m	2	1m interval
			12-23m	2	2m interval
			2-5y	1
			≥50y	1

If the clinic attendance is just for vaccination alone, no additional consultation fees are charged.

Vaccine	Against	Disease	Age	D o s e s	Dose schedule	Price per dose (SG$)
Havrix™ 1440 Adult Hepatitis A vaccine Hepatitis vaccine	Hepatitis A virus	Hepatitis A	≥19y	2	m 0 & 6-12	$90/=
Twinrix® Hepatitis vaccine	Hepatitis A virus Hepatitis B virus	Hepatitis A Hepatitis B	1-15y	2	m 0, 6-12	$120/=
			≥16y	3	m 0, 1, 6
			≥16y	4	d 0, 7, 21 & m 12
Inactivated / Fractional / Protein / Subunit / Recombinant
Engerix™-B 20 μg Hepatitis B vaccine Hepatitis vaccine	Hepatitis B virus	Hepatitis B	11-15y	2	m 0, & 6	$50/=
			≥20y	3	m 0, 1, & 6
			≥20y	4	m 0, 1, 2, & 12 or d 0, 7, 21 & m 12
Gardasil® HPV vaccine	HPV types 6, 11, 16, & 18	Genital warts Cervical cancer	9-26y	3	m 0, 2, & 6 or m 0, 1, & 4	$195/=
Cervarix® HPV vaccine	HPV types 16, & 18 (31, 33, & 45)		10-25y	3	m 0, 1, & 6 m 0, 1, & 5 m 0, 2½, 12	$195/=
V503 HPV vaccine	HPV types 6, 11, 16, 18, 31, 33, 45, 52, & 58			3	m 0, 2, & 6 or m 0, 1, & 4	$???/=

Vaccination against	Birth	1 month	3 months	4 months	5 months	12 months	15 months	18 months	6-7 years^	10-11 years^^
Tuberculosis	BCG
Hepatitis B	HepB (D1)	HepB (D2)			HepB (D3)#
Diphtheria, Tetanus, Pertussis			DTaP (D1)	DTaP (D2)	DTaP (D3)			DTaP (B1)		Tdap (B2)
Poliovirus			OPV (D1)	OPV (D2)	OPV (D3)			OPV (B1)	OPV (B2)	OPV (B3)
Measles, Mumps, Rubella						MMR (D1)	MMR (D2)##
Pneumococcal Disease			PCV (D1)		PCV (D2)	PCV (B1)
Human Papillomavirus		Recommended for females 9 to 26 years; three doses are required at intervals of 0, 2, 6 months
Influenza		Recommended annually for all children aged 6 months to <5 years and children aged 6 months to <18 years in high-risk groups

Notes:
BCG	Bacillus Calmette-Guérin
HepB	Hepatitis B vaccine
DTaP	Paediatric diphtheria and tetanus toxoid and acellular pertussis vaccine
Tdap	Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
MMR	Measles, mumps, and rubella vaccine
OPV	Oral polio vaccine
PCV	Pneumococcal conjugate vaccine
D1/D2/D3	1st dose, 2nd dose, 3rd dose
B1/B2/B3	1st booster, 2nd booster, 3rd booster
^	Primary 1
^^	Primary 5


#	3rd dose of HepB can be given with the 3rd dose of DTaP and OPV for the convenience of parents.
##	2nd dose of MMR can be given between 15-18 months

ACIP Expands PCV13 Vaccine Recommendation to Include Immunocompromised Kids, Teens
Tue, 26 Feb 2013 23:05:00 +0100 | AAFP Health of the Public
The CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand the age recommendation for administration of the 13-valent pneumococcal conjugate vaccine (PCV13) to certain individuals during its Feb. 20-21 meeting in Atlanta. Committee members also discussed and voted on a number of other vaccine-related issues of interest to family physicians. According to Jamie Loehr, M.D., of Ithaca, N.Y., the AAFP's liaison to the ACIP, the committee voted unanimously to provisionally recommend that PCV13, which is marketed by Pfizer Inc. as Prevnar 13, routinely be given to immunocompromised, PCV13-naive children and adolescents ages 6 to18 years. (Source: AAFP Health of the Public)

ACIP Expands Recommendation on PCV13 to Include Certain High-risk Kids, Teens
Tue, 26 Feb 2013 23:05:00 +0100 | AAFP Health of the Public
The CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand the age recommendation for administration of the 13-valent pneumococcal conjugate vaccine (PCV13) to certain individuals during its Feb. 20-21 meeting in Atlanta. Committee members also discussed and voted on a number of other vaccine-related issues of interest to family physicians. According to Jamie Loehr, M.D., of Ithaca, N.Y., the AAFP's liaison to the ACIP, the committee voted unanimously to provisionally recommend that PCV13, which is marketed by Pfizer Inc. as Prevnar 13, routinely be given to immunocompromised, PCV13-naive children and adolescents ages 6 to18 years. (Source: AAFP Health of the Public)

Gambia: Gambia Commences Vaccination of Cattle Against Bovine Pneumonia
Mon, 25 Feb 2013 18:36:03 +0100 | AllAfrica News: Health and Medicine
[Foroyaa]The Food and Agriculture Organisation (FAO) of the United Nations, The Government of the Republic of the Gambia, through the Ministry of Agriculture in collaboration with the FAO Country Office, officially launched an animal health mass vaccination of cattle against the Contagious Bovine Pluero Pneumonia (CBPP), in Niamina Dankunku, in the Central River Region (CRR) on Saturday, 23rd February 2013. (Source: AllAfrica News: Health and Medicine)

Crystallization and preliminary X-ray crystallographic studies of DnaJ from Streptococcus pneumoniae
Fri, 22 Feb 2013 05:00:00 +0100 | Acta Crystallographica Section F
DnaJ, cooperating with DnaK and GrpE, promotes the folding of unfolded hydrophobic polypeptides, dissociates protein complexes and translocates protein across membranes. Additionally, DnaJ from Streptococcus pneumoniae (SpDnaJ) is involved in the infectious disease process and is being developed as a potential vaccine to prevent bacterial infection. Here the expression, purification, crystallization and preliminary crystallographic analysis of SpDnaJ are reported. The crystals belong to space groups I222 or I212121 and the diffraction resolution is 3.0 Å with unit-cell parameters a = 47.68, b = 104.45, c = 234.57 Å. The crystal most likely contains one molecule in the asymmetric unit, with a VM value of 3.24 Å3 Da−1 and a solvent content of 62.1%. (Source: Acta Crystallographi...

Acute kidney injury and inflammatory immune reconstitution syndrome in mixed genotype (A/E) hepatitis B virus co-infection in HIV-associated lymphoma.
Thu, 21 Feb 2013 08:00:02 +0100 | International Journal of Clinical and Experimental Pathology
We report a first case of HIV-associated lymphoma (HAL) presenting with acute kidney injury (AKI) and inflammatory immune reconstitution syndrome (IRIS). A 39-year-old male, treated with nonsteroidal anti-inflammatory drugs (NSAIDs) for one month prior to admission, developed AKI, left testicular tumor, and recurrent swelling of the right parotid gland. A resected testicular tumor exhibited features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Renal biopsy showed hydro-degeneration of renal tubules, interstitial inflammatory cells, and a small number of lymphoma cells in the sub-capsule, compatible with acute interstitial nephritis. His renal dysfunction rapidly recovered following chemotherapy and combination antiretroviral therapy (cART). He developed pneumoni...